[Central effects of some adrenergic blocking and-or sympatholytic substances. II. Action on spontaneous motility and potentialization of pentobarbital].
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001949:Bretylium Compounds / Q000494:pharmacology; D003983:Dibenzylchlorethamine / Q000494:pharmacology; D004357:Drug Synergism; D004878:Ergotamine / Q000494:pharmacology; D006145:Guanethidine / Q000494:pharmacology; D008750:Methyldopa / Q000494:pharmacology; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D010424:Pentobarbital / Q000494:pharmacology*; D010643:Phenoxybenzamine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology*; D015016:Yohimbine / Q000494:pharmacology
D000959:Antihypertensive Agents; D001949:Bretylium Compounds; D013565:Sympatholytics; D010643:Phenoxybenzamine; D015016:Yohimbine; D003983:Dibenzylchlorethamine; D008750:Methyldopa; D011433:Propranolol; D010424:Pentobarbital; D004878:Ergotamine; D010646:Phentolamine; D006145:Guanethidine
Effets centraux de quelques substances adréno- et-ou sympatholytiques. II. Action sur la motilité spontanée et potentialisation du pentobarbital.